Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.

ABSTRACT:

Purpose

The epidermal growth factor receptor (EGFR) is recognized as a key mediator of proliferation and progression in many human tumors. A series of EGFR-specific inhibitors have recently gained Food and Drug Administration approval in oncology. These strategies of EGFR inhibition have shown major tumor regressions in approximately 10% to 20% of advanced cancer patients. Many tumors, however, eventually manifest resistance to treatment. Efforts to better understand the underlying mechanisms of acquired resistance to EGFR inhibitors, and potential strategies to overcome resistance, are greatly needed.

Experimental design

To develop cell lines with acquired resistance to EGFR inhibitors we utilized the human head and neck squamous cell carcinoma tumor cell line SCC-1. Cells

SUBMITTER: Benavente S 

PROVIDER: S-EPMC2903727 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature